ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.
Times cited: 18
Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
Times cited: 67
Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21).
Leukemia and Lymphoma.
Times cited: 10